NASDAQ:ANEB Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis $0.33 +0.33 (+82,400.00%) As of 09:36 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANEB alerts:Sign Up Key Stats Today's Range$0.33▼$0.3350-Day Range$0.00▼$0.5252-Week Range$0.00▼$3.42Volume100 shsAverage Volume38,067 shsMarket Capitalization$13.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments. The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S. Food and Drug Administration upon completion of these studies. Anebulo has established manufacturing and distribution strategies to support future commercialization, aiming to deliver a differentiated option for patients who require fast-acting, non-oral migraine relief. Founded in 2019 and headquartered in Campbell, California, Anebulo Pharmaceuticals brings together a team of industry veterans in drug delivery and neurology. By leveraging proprietary intranasal delivery technology, the company seeks to address unmet needs in migraine care and expand its development pipeline in related therapeutic areas.AI Generated. May Contain Errors. Read More Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANEB Stock News HeadlinesAnebulo Pharmaceuticals (NASDAQ:ANEB) Trading Down 8.6% - Here's WhyJuly 9, 2026 | americanbankingnews.comANEBULO PHARMAC INC by Anebulo Pharmaceuticals Inc (ANEB) Stock Price, Quote, News & HistoryJuly 1, 2026 | benzinga.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 16 at 1:00 AM | Porter & Company (Ad)Anebulo’s Selonabant Phase 1 Completion: What Investors Should Watch NextMay 8, 2026 | tipranks.comAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent UpdatesFebruary 13, 2026 | finance.yahoo.comAnebulo Pharmaceuticals stock plunges after announcing Nasdaq delisting plansFebruary 6, 2026 | in.investing.comAnebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SECFebruary 6, 2026 | finance.yahoo.comAnebulo Pharmaceuticals Announces Final Results of Tender OfferJanuary 29, 2026 | finance.yahoo.comSee More Headlines ANEB Stock Analysis - Frequently Asked Questions How have ANEB shares performed this year? Anebulo Pharmaceuticals' stock was trading at $1.01 at the beginning of 2026. Since then, ANEB stock has decreased by 67.3% and is now trading at $0.33. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) posted its quarterly earnings results on Monday, September, 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). When did Anebulo Pharmaceuticals IPO? Anebulo Pharmaceuticals (ANEB) raised $21 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 3,000,000 shares at $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO. How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anebulo Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anebulo Pharmaceuticals investors own include Hecla Mining (HL), Li Auto (LI), Norwegian Cruise Line (NCLH), PAR Technology (PAR), Transdigm Group (TDG) and Trade Desk (TTD). Company Calendar Last Earnings9/29/2025Today7/16/2026Next Earnings (Estimated)9/23/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ANEB's financial health is in the Red zone, according to TradeSmith. ANEB has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANEB CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.48 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.57% Return on Assets-68.96% Debt Debt-to-Equity RatioN/A Current Ratio6.24 Quick Ratio6.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book1.18Miscellaneous Outstanding Shares40,785,000Free Float7,912,000Market Cap$13.46 million OptionableNot Optionable Beta-1.83 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ANEB) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersThe Lithium Gold Rush Minted A New $1B UnicornThe Lithium Gold Rush Minted A New $1B Unicorn This lithium producer surpassed a $1B private valuation, joi...EnergyX | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANEB Stock Alerts